Kimryn Rathmell, Chief Executive Officer of Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, shared on LinkedIn:
“At the Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, we are working to personalize clinical care through our deep commitments to translational cancer research.
As part of this effort, I am pleased to announce Ann-Kathrin Eisfeld, MD, as Director of Precision Genomics Clinical Transformation for the OSUCCC – James, effective July 1.
Dr. Eisfeld leads as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research, where she has led innovative research focused on using genetic insights to improve diagnosis, prognosis and treatment, particularly for patients with acute myeloid leukemia – improving outlook and outcomes for many types of AML.
I want to sincerely congratulate Dr. Eisfeld on this appointment and can’t wait to see the impact her work will continue to have on the future of personalized care across the cancer continuum. Please join me in celebrating her in this exciting new role.”
Other articles about Precision Oncology and Ann-Kathrin Eisfeld on OncoDaily.